"Pinetree Therapeutics Raises $17M in Funding to Develop Targeted Protein Degraders for Oncology"
Pinetree Therapeutics Raises $17M in Series A Funding
Pinetree Therapeutics, Inc. secures Series A Funding
Pinetree Therapeutics, a biotechnology research company based in the United States, has raised $17 million in Series A funding. They are leveraging their AbReptorâ„¢ antibody degrader platform to develop targeted protein degraders for combating drug resistance in oncology. With broad applications across multiple tumor types, Pinetree Therapeutics is an ideal partner for oncology-focused pharmaceutical companies, healthcare providers, and biotech collaborators.
Funding Amount: $17 million
Industry: Biotechnology Research
Employee Count: 11-50
CEO: Ho-Juhn Song (CEO Linkedin)
What Pinetree Therapeutics needs to buy: Pinetree Therapeutics is seeking research and development partnerships, manufacturing and production services, and marketing and commercialization expertise. Companies involved in drug development, antibody-based therapies, and oncology marketing are well-positioned to collaborate with Pinetree Therapeutics and drive innovation in the field of targeted therapies.